| Literature DB >> 23575359 |
Sobia Idrees1, Usman A Ashfaq.
Abstract
BACKGROUND: HCV infection is a major health problem causing acute and chronic hepatitis. HCV E1 protein is a transmembrane protein that is involved in viral attachment and therefore, can serve as an important target for vaccine development. Consequently, this study was designed to analyze the HCV E1 protein sequence isolated in Pakistan to find potential conserved epitopes/antigenic determinants.Entities:
Mesh:
Substances:
Year: 2013 PMID: 23575359 PMCID: PMC3637199 DOI: 10.1186/1743-422X-10-113
Source DB: PubMed Journal: Virol J ISSN: 1743-422X Impact factor: 4.099
Figure 1A. Secondary structure of the HCV E1 protein of Pakistani origin, Helices are labeled as H1, H2; Beta turn as β; Gamma turn as χ and Beta hairpin as ⥰. B. Predicted 3 Dimensional structure of the HCV Envelope protein 1 using Homology Modelling. C. Ramachandran plot showing residues in the most favorable region and disallowed regions. D. Z-score showing the quality of the 3D structure.
Figure 2HCV EI protein glycosylation sites.
A. The HCV E1 protein of Pakistani origin showing 5 glycosylation sites highlighted in red at positions 5, 18, 43, 114 and 134. B. Multiple sequence alignment showing conserved glycosylation sites at positions 5, 18, 43, 114 and 134 in the HCV E1 proteins isolated from the different region of the world.
Predicted B-cell epitopes
| 49 | TPVTPTVAVRYV | 0.994 |
| 32 | TPGCIPCVQDGN | 0.965 |
| 13 | TNDCPNSSIVYE | 0.87 |
| 153 | IFDILGGAHWGM | 0.702 |
| 96 | VGQAFTFRPRRH | 0.538 |
| 123 | SGHRMAWDMKMN | 0.292 |
Discontinuous epitopes predicted from the 3D structure of the E1 protein using DiscoTop online server
| 109 | THR | 3 | -2.545 | -2.598 |
| 110 | VAL | 7 | -2.183 | -2.737 |
| 111 | GLN | 3 | -1.235 | -1.438 |
| 112 | THR | 1 | -1.964 | -1.853 |
| 113 | CYS | 1 | -3.211 | -2.957 |
| 114 | ASN | 9 | -2.677 | -3.404 |
| 155 | ASP | 1 | -2.341 | -2.187 |
| 156 | ILE | 1 | -1.626 | -1.554 |
Figure 3Predicted B-cell epitopic regions of the E1 protein 3D structure. B-cell epitopic regions are shown in yellow color.
MHC class I binding peptides on the basis of antigenicity
| 83 | ATTASVRSH | HLA-A1/HLA-A*1101/HLA-A3/HLA-A*3101/HLA-A*3302/HLA-B*5801 | 0.9061 |
| 154 | MNWTPAVGM | HLA-A2/HLA-A*0201/HLA-A*3101/HLA-A20/HLA-B*2705/HLA-B*3501/HLA-B*5201/HLA-B*5301/HLA-B*5401/HLA-B*51/HLA-B7/HLA-B*0702/HLA-B8/HLA-Cw*0401/MHC-Ld | 1.1593 |
| 160 | VGMVVAQVL | HLA-A*0205/HLA-A24/HLA-A20/HLA-A2.1/HLA-B14/HLA-B*2702/HLA-B*2705/HLA-B*3701/HLA-B*3801/HLA-B*3901/HLA-B*3902/HLA-B*4403/HLA-B*5101/HLA-B*5102/HLA-B*5103/HLA-B*5201/HLA-B*5301/HLA-B*51/HLA-B60 | 0.5535 |
| 178 | LGGAHWGML | HLA-A*0205/HLA-A24/HLA-A2.1/HLA-B14/HLA-B*2705/HLA-B*3701/HLA-B*3901/HLA-B*3902/HLA-B*5101/HLA-B*5102/HLA-B*5103/HLA-B*5201/HLA-B*51/HLA-B60/HLA-B62/HLA-B7/HLA-B*0702/HLA-Cw*0301/HLA-Cw*0401/HLA-Cw*0602/HLA-Cw*0702/MHC-Db/MHC-Dd/MHC-Kb/MHC-Kd | 0.6771 |
| 90 | SHVDLLVGA | HLA-A*3302/HLA-B*3801/HLA-B*3901/HLA-B*5401/HLA-Cw*0702 | 0.9645 |
MHC class II binding peptides on the basis of antigenicity
| 12 | LTNDCPNSS | DRB1_0305-309, DRB1_0311, DRB1_0401, DRB1_0421, DRB1_0426, DRB1_1107 | 0.4554 |
| 19 | WTPVTPTVA | DRB1_0101, DRB1_408 | 0.7528 |
| 28 | VRYVGATTASV | DRB1_0101, DRB1_0305, DRB1_0309, DRB1_0402, DRB1_0404, DRB1_0405, DRB1_0408, DRB1_0410, DRB1_0423, DRB1_0813, DRB1_1107 | 0.5239 |
| 30 | YVGATTASV | DRB1_0101, DRB1_0305, DRB1_0309, DRB1_0401, DRB1_0402, DRB1_0404, DRB1_0405, DRB1_0408, DRB1_0410, DRB1_0421, DRB1_0423, DRB1_0426, DRB1_0701, DRB1_0703, DRB1_0801, DRB1_0802, DRB1_0813, DRB1_1101, DRB1_1114, DRB1_1120, DRB1_1128, DRB1_1302, DRB1_1305, DRB1_1307, DRB1_1321, DRB1_1323 | 1.0175 |
| 28 | VRYVGATTA | DRB1-0102, DRB1-0306-0308, DRB1_0311, DRB1_1104, DRB1_1106, DRB1_1107, DRB1_1311, DRB1_1501, DRB1_1506, DRB5_0101, DRB5_0105 | 0.4463 |
Figure 4The HCV E1 protein model showing an epitopic location in the structure.
Conservation and variability analysis of B-cell and T-cell epitopes in comparison with HCV E1 proteins of other regions
| VGQAFTFRPRRH | V | V | VGQ | VGQAFTF | VGQ | VGQ | VGQAFTFRPRRH | VGQAF | ||
| TPVTPTVAVRYV | TPV | TPVTPTVAVRYV | TPVTPTVAVR | |||||||
| TPGCIPCVQDGN | TPGC | TPGC | TPGC | TPGC | TPGCIPCVQDGN | |||||
| TNDCPNSSIVYE | TNDC | TNDC | TNDC | TNDCPNSSIVYE | TNDC | TNDC | TNDCPNSS | TNDCPNSSIVYE | TNDCPNSSIVYE | TNDCPNSSIVYE |
| ATTASVRSH | A | ATTAS | A | A | ATTASVRSH | |||||
| MNWTPAVGM | MNW | MNW | MNW | MNW | MNW | MNW | MNW | MNW | ||
| VGMVVAQVLRL | V | |||||||||
| LGGAHWGML | L | |||||||||
| SHVDLLVGA | SHVD | SHVDLLVGA | SHVDL | |||||||
| LTNDCPNSS | LTNDC | LTNDCPNSS | ||||||||
| WTPVTPTVA | W | W | W | W | W | WTPV | W | W | WTPVTPTVA | WTPVTPTVA |
| VRYVGATTASV | V | V | V | VRYVGATTASV | VR | |||||
| YVGATTASV | Y | YVGATTASV | ||||||||
| VRYVGATTA | V | V | V | VRYVGATTA | VR |
Variable residues in epitopes are shown in bold.